Literature DB >> 10987268

Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer.

N Haruki1, H Saito, Y Tatematsu, H Konishi, T Harano, A Masuda, H Osada, Y Fujii, T Takahashi.   

Abstract

Inactivation of p53, which represents the most prevalent genetic alteration in lung cancer, has been shown to play a crucial role in the acquisition of genomic instability. We examined 44 lung cancer specimens to search for mutations in the CHK1 and CHK2 genes, which have been suggested to play roles in regulating p53 after DNA damage. We found that the CHK2 gene was somatically mutated in lung cancer in vivo, although at a low frequency, and that a previously undescribed shorter isoform of CHK1 was expressed preferentially in small cell lung cancer in a tumor-predominant manner. Additional studies are warranted to investigate the functional significance of these changes as well as the potential involvement of other components in this important pathway to maintain genomic stability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987268

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

2.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

3.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

4.  Viral transport of DNA damage that mimics a stalled replication fork.

Authors:  Jaana Jurvansuu; Kenneth Raj; Andrzej Stasiak; Peter Beard
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.

Authors:  Szilvia Solyom; Katri Pylkäs; Robert Winqvist
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

6.  Chk2 activation and phosphorylation-dependent oligomerization.

Authors:  Xingzhi Xu; Lyuben M Tsvetkov; David F Stern
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

7.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 8.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

Review 9.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

10.  Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN.

Authors:  Sarah A Martin; Toru Ouchi
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.